Addendum
Addendum to Commission A12-16 Saxagliptin/metformin
Report documents
-
Addendum
Addendum to Commission A12-16 Saxagliptin/metformin
Press releases
IQWiG assessed information subsequently provided by the manufacturers on two dossiers
Now hint of added benefit of crizotinib in symptoms and quality of life / no change regarding saxagliptin/metformin
Additional information
Federal Joint Committee (G-BA)
2013-05-02 A G-BA decision was published.
Project details
- Project no.
- A13-14
- Commission
- Commission awarded on 27.03.2013 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed